Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 214579, held by Eugia Pharma. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 214579 (Ephedrine Sulfate), held by Eugia Pharma, was first approved by FDA on Jun 14, 2021, with 1 approved supplement and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 14, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Mar 31, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 14, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters